CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval

CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension.

Females’ immune system edges out males but at a cost of higher autoimmune risk

A review article highlights how two X chromosomes in females influence immune system composition and function, leading to faster infection clearance and stronger vaccination responses

February 23, 2024

Opinion | ‘It’s Much More Severe, and It’s Much More Dangerous’: What We Heard This Year

In place of our usual “What We Heard This Week” feature, and as part of our year-end wrap-ups, we’ve selected some of the best quotes

December 30, 2024

A STAT analysis shows how top drug companies are starting to take action on climate

This article is adapted from STAT’s exclusive analysis in the STAT Report: “Climate rankings: How top drug companies measure up in combating climate change.” Drug companies

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.